WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007000769) RECOMBINANT INTERFERON &agr;2 (IFN&agr;2) MUTANTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/000769    International Application No.:    PCT/IL2006/000754
Publication Date: 04.01.2007 International Filing Date: 28.06.2006
IPC:
A61K 38/21 (2006.01)
Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE [IL/IL]; P.O. Box 95, 76100 Rehovot (IL) (For All Designated States Except US).
SCHREIBER, Gideon [IL/IL]; (IL) (For US Only).
ROISMAN, Laila, C. [IL/IL]; (IL) (For US Only).
JAITIN, Diego [IL/IL]; (IL) (For US Only).
KALIE, Eyal [IL/IL]; (IL) (For US Only)
Inventors: SCHREIBER, Gideon; (IL).
ROISMAN, Laila, C.; (IL).
JAITIN, Diego; (IL).
KALIE, Eyal; (IL)
Agent: WEBB, Cynthia; WEBB & ASSOCIATES, P.O. Box 2189, 76121 Rehovot (IL)
Priority Data:
60/694,810 29.06.2005 US
Title (EN) RECOMBINANT INTERFERON &agr;2 (IFN&agr;2) MUTANTS
(FR) MUTANTS D'INTERFERON ?2 (IFN?2) DE RECOMBINAISON
Abstract: front page image
(EN)The present invention provides IFN&agr;2 mutants and active fragments, analogs, derivatives, and variants thereof that have improved specific agonist or antagonist activity as compared to wild-type IFN&agr;2. The present invention further provides pharmaceutical compositions comprising IFN&agr;2 mutants useful for treating or preventing cancer, autoimmune diseases, infectious diseases or disorders associated with increased expression of IFN&agr;2.
(FR)La présente invention concerne des mutants IFNa2 et des fragments actifs, des analogues, des dérivés et des variants de ceux-ci qui possèdent une activité agoniste ou antagoniste spécifique améliorée comparée à IFNa2 de type sauvage. Cette invention concerne aussi des compositions pharmaceutiques comprenant des mutants IFNa2 qui conviennent pour traiter ou prévenir le cancer, des maladies auto-immunes, des maladies infectieuses ou des pathologies associées à une expression accrue de IFNa2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)